Aug 2026· Journal of Peptide Science· Vol 32· 0 citations· 48 references
Medicine
TL;DR
Results suggest that posttranslational modifications of αSyn do not induce significant secondary structural changes in monomeric αSyn, suggesting that the modifications themselves do not induce significant secondary structural changes in monomeric αSyn.
Abstract
α‐Synuclein (αSyn) is a major component of pathogenic Lewy bodies and Lewy neurites and is closely associated with Parkinson's disease. Among the various posttranslational modifications of αSyn, several have been implicated in the degeneration of dopaminergic neurons and are thought to promote Parkinson's disease through enhanced misfolding, aggregation, and accumulation of αSyn. Two such modifications, phosphorylation at Ser129 (S129Phos) and hydroxylation at Tyr136 (Y136DOPA), exert distinct effects on αSyn aggregation: S129Phos has been reported to either inhibit or promote aggregation, whereas Y136DOPA induces the formation of short oligomeric species. To gain insight into the molecular basis underlying the initiation of αSyn multimerization, we semisynthesized αSyn carrying either S129Phos or Y136DOPA and prepared recombinant unmodified full‐length αSyn as a control. Vacuum‐ultraviolet circular dichroism (VUVCD) spectroscopy revealed that these αSyn variants in their monomeric states possessed essentially identical secondary structures. These results suggest that the modifications themselves do not induce significant secondary structural changes in monomeric αSyn.
The structure of α-synuclein is predominantly α-helical when bound to cellular membranes. However, under pathological or destabilizing conditions, this α-helical structure transitions into β-sheet-rich conformations, promoting protein aggregation and formation of Lewy bodies (LBs) in neurodegenerative disorders such as...
Hyeon Jin Kim, Da Hye Kim, Chang-Woo Han et al.· International Journal of Bio...· 0 citations
The α-synuclein (aSyn) pathology is a predominant feature of synucleinopathies such as Parkinson's disease (PD). Triggers that may induce aSyn aggregation are not completely understood, but include post-translational modifications. One such modification is aSyn truncation exposing the N-terminal glutamine 79 residue th...
A. Bluhm, Merle Großmann, Charlotte Minister et al.· Neurochemistry International· 0 citations
A mechanistic model in which selectivity for aggregated aSyn arises from an emergent mesoscale interface combining a polyelectrolyte brush with recurrent core hotspots is presented, establishing full‐length, brain‐derived fibril ensembles as a practical framework for understanding ligand recognition at amyloid surfaces...
Carlos Pintado-Grima, Oriol Bárcenas, G. Tesei et al.· Protein Science· 0 citations
A proteoform-by-environment model for IDP structure is established, in which phosphorylation effects are not fixed but are rewritten by the surrounding chemical environment, which distinguishes broad contact accessibility from the residue-level contacts that dominate each condition.
Ashlyn N. Dollar, Daniel W. Kelley, Ian K. Webb· Journal of the American Chem...· 0 citations
Multiple System Atrophy (MSA) and Parkinson's Disease (PD) are neurodegenerative diseases characterized by abundant α-synuclein (αSyn) aggregation in the brain. Compared to PD patients, MSA patients have more widespread neurodegeneration and a more aggressive disease course. PD-related αSyn pathology is primarily neuro...
Anne-Line Strange Laursen, K. Willén, Alexis Fenyi et al.· Neurobiology of Disease· 0 citations
Significance Parkinson’s Disease and several other neurodegenerative diseases are driven by misfolding and aggregation of the neuronal protein α-synuclein. We studied a transgenic mouse model expressing the Parkinson’s-associated A53T mutant human α-synuclein, that succumbs with dystonic limbs at ~8 mo, with presence o...
Maria Nagy, W. Fenton, A. Horwich· Proceedings of the National...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.